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Abstract
Background: Rheumatoid arthritis (RA) most often begins in females in the fourth-fifth decade of
their life, suggesting that the aging of the immune system (immunosenescence) has a major role in
this disease. Therefore, in the present study, we sought to investigate the effect of age on arthritis
susceptibility in BALB/c mice using the proteoglycan (PG)-induced arthritis (PGIA) model of RA.
Results:  We have found that young, 1-month-old female BALB/c mice are resistant to the
induction of PGIA, but with aging they become susceptible. PG-induced T cell responses decline
with age, whereas there is a shift toward Th1 cytokines. An age-dependent decrease in T cell
number is associated with an increased ratio of the memory phenotype, and lower CD28
expression. Antigen-presenting cells shifted from macrophages and myeloid dendritic cells in young
mice toward B cells in older mice. The regulatory/activated T cell ratio decreases in older mice
after PG injections indicating impaired regulation of the immune response.
Conclusion: We conclude that immunosenescence could alter arthritis susceptibility in a very
complex manner including both adaptive and innate immunities, and it cannot be determined by a
single trait. Cumulative alterations in immunoregulatory functions closely resemble human disease,
which makes this systemic autoimmune arthritis model of RA even more valuable.
Background
Immunosenescence, the age-related decline of immune
function, is associated with a broad spectrum of changes
affecting both innate and adaptive immunity [1,2]. The
frequency of infections, malignancies, and autoimmune
diseases increases with age due to the decline of normal
immune surveillance and dysregulation of immune
responses [2,3]. Aging is a definitive risk factor for rheu-
matoid arthritis (RA), and numerous studies focused on
the "premature immunosenescence" in RA [3-6].
Although several markers of immunosenescence have
been described both in mice and humans, there are still
gaps in our understanding; in turn, the incomplete under-
standing of how immunosenescence gives rise to autoim-
munity.
Alteration of the T cell repertoire is a major contributor to
the age-related decline of adaptive immunity [3,6,7]. For
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example, thymus atrophy leads to decreased T cell output
[8] and reduced T cell receptor (TCR) rearrangement [4].
This decreased thymic function poses a stress on periph-
eral T cell expansion [9] simultaneously leading to the
rapid shortening of their telomere regions [4,10]. In RA, T
cells show evidence of senescence 20–30 years earlier than
T cells from healthy individuals [4,5].
On the molecular level, age-related alterations in TCR sig-
naling [11] and the loss of CD28, a key costimulatory
molecule on T cells, have been described. CD28null
CD4+ T cells are less responsive to regulatory T cell (Treg)-
mediated suppression [9,12] and senescent human T cells
aberrantly express costimulatory molecules KIR2DS2,
NKG2D, and CX(3)CR1, instead of their normal costimu-
latory molecule CD28 [13,14]. In addition, diminished
expression of CD40L, another costimulatory molecule, by
aged T cells may not provide sufficient help to B cells [15].
In contrast, increased expression of CD70, has been
detected in RA patients, with the potential of lowering the
threshold of TCR signaling [16]. Collectively, these abnor-
malities in T cell activation could facilitate the develop-
ment of autoimmunity [9,17]. B cells are also affected,
and in the process of immunosenescence these cells
exhibit a decreased capacity of antibody production
against foreign antigens and increased autoantibody pro-
duction [18]. Impaired humoral response is possibly due
to decreased bone marrow output of naive conventional
(follicular) B cells, which is compensated in the periphery
with marginal-zone-, CD5+ B1-like-, and memory, B cells
[18]. Instead of high-affinity IgG type antibodies, the pro-
duction of low-affinity cross-reactive and often autoreac-
tive IgM antibodies was observed in aging individuals
[19]).
Proteoglycan (PG) aggrecan-induced arthritis (PGIA) is a
murine model of RA. Repeated intraperitoneal immuniza-
tions with human cartilage PG leads to joint inflamma-
tion, progressive cartilage destruction, bone erosion and
ankylosis in peripheral joints of genetically susceptible
mice [20]. The mechanism of the disease is based upon
the cross reactive immunity, at both T cell response and
antibody production, between the mouse (self) and
human PG used for immunization [21-23]. Autoimmune
features of PGIA such as autoantibody production as well
as the cytokine profile in serum closely resemble RA. The
clinical appearance of PGIA, the greater susceptibility of
aging female mice, and the importance of genetic predis-
position are additional characteristics shared with RA
(reviewed in [24]).
Almost two decades ago, we found that aging female
BALB/c mice are more susceptible to PGIA than young
animals, and since then we have routinely used "retired
breeder" females to induce the disease [24,25]. However,
the age-related increase in susceptibility to PGIA has never
been investigated in a systematical study. Therefore, the
aim of this study was to examine the effect of age on PGIA
susceptibility in BALB/c mice, and to find immunologic
parameters that may contribute to the age-related increase
in disease development. Using a standard immunization
protocol, here we show, for the first time, that young (1-
month-old) BALB/c mice are fully resistant to PGIA; 2–3-
month-old mice develop relatively mild arthritis with
delayed onset, whereas mice at 4-months of age or older
at the beginning of immunizations are highly susceptible
to PGIA. Immunosenescence in BALB/c mice is associated
with changes in their T cell repertoire. An age-related
expansion of CD4+CD28low T cells, together with a shift
toward a decreased ratio of regulatory/activated (Treg/
Tact) CD4+ T cells in secondary lymphoid organs of PG-
immunized aging mice have been found in correlation
with a shift in the cytokine balance toward the Th1 phe-
notype. These complex age-related changes may result in
partial loss of control over T cell responses, which, in turn,
can lead to autoimmunity and arthritis development.
Results
Susceptibility to PGIA increases with age
RA in humans most often begins in the forth-fifth decade
of life with female dominance; similar to this, older
female BALB/c mice have been found to be more suscep-
tible to PGIA than young females [24,25]. Therefore, we
performed a systematic study, using side-by-side immuni-
zations with PG in DDA adjuvant on eight different age
groups of BALB/c mice (Figure 1, Table 1). The 4–11-
month-old groups developed the highest disease severity
(arthritis score: 10.8–14.6) with 85–100% incidence and
early onset (Figure 1). The 2–3-month-old mice showed
lower incidence (71–83%) and less severe arthritis (arthri-
tis score: 5.8–9.6) accompanied by delayed onset (Figure
1). The 1-month-old group was essentially resistant to
PGIA: the disease incidence was less than 5% and the
arthritis score was only 1.6 ± 0.3 (Figure 1).
Evaluation of the age-related changes in the immune 
response to PG
To clarify the reason for the profound differences in PGIA
susceptibility, first we evaluated the age-related changes in
the PG-induced immune responses (in vitro T cell
response, and serum cytokine and antibody levels). PG-
induced in vitro T cell proliferation and IL-2 production
decreased linearly and significantly with age (Figures 2A
and 2B). PG-stimulated spleen cell cultures from older
mice (dramatically from the age of 7 months) secreted sig-
nificantly less IL-4, IL-6, IL-17 and IFNγ (Figure 2C). IL-6
production also showed linear decrease with age; IL-4 and
IL-17 levels were similar in the 1–5-month-old groups,
and significantly less in older mice (Figure 2C). PG-
induced production of IFNγ and TNFα was high in groupsImmunity & Ageing 2009, 6:8 http://www.immunityageing.com/content/6/1/8
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between 1 to 5 months of age, and then declined (Figure
2C). The IFNγ: IL-4 ratio, which has been used to charac-
terize the Th1/Th2 balance [26,27], was significantly
higher in mice older than 2 months than in the 1-month-
old (essentially PGIA-resistant) mice (Figure 2C),
although the antigen-specific cytokine production (both
IFNγ and IL-4) dramatically declined after 7 months of
age.
As potential biomarkers of arthritis in the aging groups,
we correlated the serum cytokine and antibody levels with
the clinical parameters. Although there were a number of
significant differences, none of the measured cytokines in
serum showed a clear correlation with the clinical param-
eters of the corresponding age groups (data not shown).
On the contrary, serum antibody levels showed significant
positive correlation with disease severity (arthritis score)
(Table 1). Notably, the 1-month-old, essentially PGIA-
resistant, group had lower antibody concentrations than
most of the other groups that had developed arthritis
(Table 1).
Age-related changes in the cellular composition of 
peritoneal lavage fluid (PLF), spleen, and blood in naive 
non-immunized mice
To characterize the cell populations that participate in the
control of local immunological events, eventually affect-
ing arthritis susceptibility and severity, we analyzed T cells
and antigen presenting cells (APCs; B cells, dendritic cells
and macrophages) in tissue compartments that were pri-
marily exposed to the antigen. We hypothesized that early
activation events should take place in the peritoneum
(PLF population), followed by changes in spleen, and
blood [28].
In the blood, the percentage of T cells decreased substan-
tially, while the ratio of CD44high  (activated/mem-
ory):CD62Lhigh (naive) CD4+ T cells increased with age,
but both remained at constant levels and ratios in the
spleen and the PLF (Figures 3A and 3B). CD28 expression
on CD4+ T cells decreased with age in the PLF, but it was
similar in all age groups in the blood and spleen (Figure
3C). CD28 expression was highest for PLF CD4+ T cells in
1- to 3-month-old mice (Figure 3C). The percentage of
Tregs decreased in the PLF and blood, but increased in the
spleen with age (Figure 3D).
Table 1: Serum antibody levels in aging BALB/c mice immunized with human PG
Age Heteroantibody (mg/ml)
(anti-human PG)
Autoantibody (μg/ml)
(anti-mouse PG)
(months) n IgG1 IgG2a IgG1 IgG2a
1 48 3.32 ± 0.26 0.69 ± 0.12 41.6 ± 6.0 39.6 ± 7.3
2 34 5.61 ± 0.33† 1.40 ± 0.24† 111.1 ± 8.2* 86.7 ± 9.6*
3 30 7.88 ± 0.57† 0.66 ± 0.14 108.5 ± 11.7* 104.5 ± 22.5*
4 27 5.72 ± 0.44† 1.71 ± 0.29† 50.0 ± 7.3 91.3 ± 23.5*
5 17 6.68 ± 0.47† 1.09 ± 0.23 86.3 ± 8.5* 33.6 ± 13.5
7 20 6.43 ± 0.61† 0.86 ± 0.13 63.1 ± 7.4 45.8 ± 8.8
9 28 5.65 ± 0.52† 1.05 ± 0.13 65.7 ± 6.6 68.2 ± 14.3
11 9 2.50 ± 0.64 0.50 ± 0.11 46.0 ± 15.9 30.4 ± 8.2
Serum levels of PG-specific hetero- and autoantibodies (against human and mouse
PG, respectively) and number of animals in the individual age groups. Age (months) indicate when the first PG injection was given; animals were 
sacrificed 87 days later, when serum samples were collected. Significantly (p < 0.05) higher †heteroantibody and *autoantibody concentrations 
compared to the 1-month-old group (bold face) are indicated.
Development of proteoglycan (PG) induced arthritis (PGIA)  in female BALB/c mice immunized with PG at different ages Figure 1
Development of proteoglycan (PG) induced arthritis 
(PGIA) in female BALB/c mice immunized with PG 
at different ages. Arthritis scores are indicated on the y-
axis and the experimental period on the x-axis. Incidence is 
shown as percent in brackets next to the symbols of each age 
group. The first PG immunization was given on day 0, and 
arrows on the x-axis show the second and third PG injec-
tions, given on days 21 and 42. Animals were scored 3 times 
a week, and a visual score from 0 to 4 of each paw was given 
as described in the Methods. Number of animals in each 
group sacrificed on day 87 is shown in Table 1.
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In addition to the significant changes in the T cell compo-
sition with age, there were alterations in the proportions
of APCs as well. The number of conventional B cells
increased during the first 5 months of age, especially in
the PLF (Figure 3E). B1 cells represented a major popula-
tion at all ages in the PLF, but their percentage decreased
significantly in the spleen between 1 and 3 months of age
(Figure 3F). (Note: in the spleen, transitional B cells and
marginal zone B cells are also included in the B1 popula-
tion). The percentage of macrophages and dendritic cells
(especially those of myeloid origin, data not shown)
decreased between 1 and 5 months of age in the PLF, but
remained approximately the same in the spleen (Figure
3G and 3H).
Regulatory and activated T cell proportions change with 
age upon PG immunization
There were significant age-dependent changes in the Treg
population (Figure 3D). Activation of T cells is a prerequi-
site for the development of PGIA [29], while Tregs are
thought to suppress autoimmunity [30]. Therefore we
sought to investigate the effect of PG immunization on
the ratio of regulatory (CD25highFoxP3+) and activated
(CD25high) CD4+ T cells (Treg and Tact, respectively) in
the different age groups, to determine if the ratio of these
cells correlated with the age-related differences in PGIA
susceptibility (Figure 1).
The Treg/Tact ratio decreased in the PLF by the end of the
immunization regime, when compared to the naive mice
in all age groups (Figure 4A). However, there was a
marked increase in Tregs after the second immunization
in the PLF of 1-month-old mice when compared to all
other groups (Figure 4A). In the spleen, the Treg/Tact ratio
was significantly lower in the 4–11-month-old groups
than in the 1-, and 2–3-month-old groups of naive ani-
mals, and consistently declined throughout the immuni-
zation period (Figure 4B).
Figure 4C shows representative flow cytometry panels and
summarizes the regulatory and activated T cell ratios in
the PLF and spleen of 1 month-old, 2–3-months-old, and
4–11-months-old mice 12 days after the second i.p.
immunization. This time point was chosen because the T
cells primed after the first PG/DDA injection, are reacti-
vated after the second injection, and might be involved in
the initiation of arthritis [28]. Although the number of
Treg cells also increased during aging, the CD25highCD4+
(activated) T cell percentage in the PLF and spleen was
several-fold higher in 4–11-month-old mice than in the
younger mice after the second immunization (Figure 4C).
This observation indicates that a continuous decline of
Treg/Tact ratio is mostly affected by the oligoclonal expan-
sion of PG-specific CD25+CD4+ activated T cell, rather
than a slight increase of Treg cells (Figure 4C).
PG-specific in vitro T cell responses in different age groups of  PG-immunized mice Figure 2
PG-specific in vitro T cell responses in different age 
groups of PG-immunized mice. (A) PG-specific T cell 
proliferation (expressed as Δcpm), and (B) IL-2 production 
(expressed as Δcpm of CTLL-2 cells). (C)PG-induced in vitro 
production of TNFα, IFNγ, IL-17, IL-4 and IL-6 (Δpg 
cytokine/million cells). Open bars in the right-bottom corner 
of Panel C show the IFNγ:IL-4 ratios of the different age 
groups. Significantly lower (*p < 0.05 or **p < 0.01) or higher 
(†p < 0.05) values are indicated.
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Age-related changes in the cellular composition of the peritoneal lavage (PLF), spleen, and blood of naive (non-immunized)  BALB/c mice Figure 3
Age-related changes in the cellular composition of the peritoneal lavage (PLF), spleen, and blood of naive 
(non-immunized) BALB/c mice. Upper panels (A-D) show the changes of the T cell repertoire: (A)T cell percentage, (B) 
CD44high (memory): CD62Lhigh (naive) CD4+ T cell ratio, (C) CD28 expression on CD4+ T cells, and (D) Treg ratio. Lower 
panels (E-H) summarize the age-related changes in APC composition in the PLF and spleen: (E) conventional B cells, (F) B1 
cells (#In the spleen this cell population is comprised of B1 cells, transitional B cells and marginal zone B cells), (G) macro-
phages (F4/80+ cells), and (H) dendritic cells (CD11c+ cells). Data represent the mean ± SEM (n = 4–5 mice per group). Values 
were significantly (p < 0.05) *lower or †higher than those measured in the 1-month-old group as indicated.
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Figure 4 (see legend on next page)
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Discussion
The major goal of this study was to identify age-associated
alterations in the functions and regulation of the immune
system that may influence arthritis susceptibility in a
genetically identical (inbred BALB/c) strain of mice.
Increasing incidence of RA with age has been repeatedly
shown in the human population [31]. Similarly, in the
PGIA model of RA, we observed that adolescent young (1-
month-old) mice are completely resistant to arthritis, but
with age they become fully susceptible to the disease.
We found that T cell responses to the immunizing human
PG (both proliferation and cytokine production)
decreased with age, which, surprisingly, inversely corre-
lated with arthritis onset and severity. In contrast to this,
in a separate study on a limited number of mice, we found
significantly lower autoreactive (mouse PG-specific) T cell
responses in young than in old mice (F. Boldizsar and TT
Glant, unpublished data). Collectively, these results sug-
gest that, while in young mice an effective regulation of
the immune response to PG still exists in older mice these
mechanisms are partially lost. This "physiological" loss of
control may lead to sustained activation of autoreactive T
cells and auto-antibody production, directing the
immune system against self antigen and culminating in
joint inflammation in genetically susceptible animals.
Suppression of autoreactivity by Tregs has been shown in
other autoimmune disease models [32-36]. Therefore, a
candidate cell population that could be responsible for
the age-related decline of the control over T cell reactivity
in PGIA is Tregs. Indeed, in arthritis-resistant young mice,
upon repeated PG injections, there was a Treg expansion,
while in older mice the balance of regulatory/activated
CD4+ cells shifted in favor of activated cells. The expan-
sion of Tregs became especially evident locally in the peri-
toneal cavity after the second i.p. PG injection in 1-
month-old mice (Figure 4). This period is critical in the
development of PGIA, since the previously differentiated,
potentially autoreactive cells are reactivated and the
autoimmune attack on the joints begins at this time [28].
We believe that local Treg preponderance in younger mice
(Figures 4A–B) at this stage of PG-immunization is
responsible for the effective control of immune response,
thus preventing autoimmunity.
Because PGIA is associated with Th1 dominance [27,37],
special attention was given to the Th1/Th2 cytokine bal-
ance. The IFNγ: IL-4 ratio shifted toward the Th1 direction
in the older, arthritis-susceptible mice, while in the arthri-
tis-resistant 1-month-old group these two signature
cytokines were produced in approximately equal
amounts. IFNγ has been shown to be a key cytokine in
PGIA, whereas IL-4 and IL-10 ameliorate the disease
[27,37]. The counterbalance of these cytokines in PGIA
has been shown in KO mice. While IFNγ-deficient BALB/
c mice developed less severe arthritis, IL-4-/- mice in the
same background aggravated the response to PG immuni-
zation: an earlier onset with more severe inflammation
was detected when compared to age- and gender-matched
wild-type mice [38,39]. Our present study indicates that,
although the amounts of both cytokines declined in aging
animals, aging seems to lead to Th1 "dominance" upon
PG immunization. However, whether the effective
amounts of these cytokines or their ratio are more critical,
remains an open question.
Besides the alterations in the PG-induced immune
responses, age-related physiological changes of the
immune system (maturation followed by immunosenes-
cence) could also explain the differences in PGIA suscep-
tibility of the different age groups. Therefore, we also
examined the age-related immune system of naive, non-
immunized, BALB/c mice. A detailed cellular analysis
showed that the proportion of T cells decreased with age
in the blood, and this was accompanied by an increase of
the proportion of conventional B cells in the spleen and
PLF of naive mice. This decreased T cell ratio was most
likely due to the involution of the thymus, resulting in
decreased thymic T cell output, and narrowing of the T cell
repertoire [8]. On the other hand, the memory T cell pool
showed expansion, while the naive T cell pool showed
contraction in aging animals [7]. Indeed, a shift toward
the memory phenotype (CD44high) in CD4+ T cells could
Changes in the ratio of regulatory (CD25highFoxP3+) and activated (CD25high) CD4+ T cells in (A) the PLF and (B) the spleen of  1-, 2–3-, or 4–11-month-old mice through the immunization period Figure 4 (see previous page)
Changes in the ratio of regulatory (CD25highFoxP3+) and activated (CD25high) CD4+ T cells in (A) the PLF and 
(B) the spleen of 1-, 2–3-, or 4–11-month-old mice through the immunization period. Values in the plots show the 
mean ± SEM calculated from the data of 3–12 mice in each group. Significantly (p < 0.05) lower values in the 4–11-month-old 
group are indicated [(A)*2–3-month-old and 4–11-month-old versus 1-month-old, (B)#4–11-month-old versus 1-month-old 
and 2–3-month-old group]. (C)Representative flow cytometric contour plots show the distribution of CD4+ T cells based on 
CD25 and FoxP3 staining 12 days after the second PG immunization in the PLF and spleen. Percent (mean ± SEM) of regulatory 
(CD25highFoxP3+) CD4+ T cells (upper right quadrant), and activated (CD25high) CD4+ T cells (upper left quadrant) are 
shown. Values in the plots were calculated from the data of 3–12 mice (as indicated above the panels). Significant (p < 0.05) dif-
ferences are indicated (†2–3-month-old and 4–11-month-old groups versus 1-month-old group; ‡4–11-month-old group versus 
1-month-old and 2–3-month-old groups).Immunity & Ageing 2009, 6:8 http://www.immunityageing.com/content/6/1/8
Page 8 of 11
(page number not for citation purposes)
be detected in the blood. The expression of CD28 co-stim-
ulatory molecule decreased with age on helper T cells in
the PLF, but not on spleen and blood T cells. Accumula-
tion of CD28null CD4+ T cells is often associated with
immunosenescence [17]. The absence of this key costim-
ulatory molecule is believed to result in perturbed T cell
signaling, which could contribute to autoimmunity [17].
In sum, we conclude that the aging processes affect both T
and B cells, which observations are in line with previous
reports [7,40]. Since PGIA is both T- and B-cell (autoanti-
body)-dependent [24,41], the age-related cellular and
phenotypic changes could profoundly affect arthritis sus-
ceptibility.
APCs play a critical role in initiating and regulating the
immune response. Dendritic cells and B cells (as APCs)
support Th1 polarization, while macrophages support the
differentiation of Th2 effector cells [42]. Therefore, we
also analyzed the age-related changes in the composition
of APC populations in different compartments of the
immune system upon i.p. PG immunization. In the peri-
toneum, there was a decrease of APCs of myeloid origin,
and an increase of B cells in the first 3–5 months of age.
In younger mice, there were more myeloid APCs (DCs
and macrophages), while after 5 months, B cells domi-
nated at the site of antigen inoculation (peritoneum). This
shift in the APC composition coincided with an increase
in arthritis susceptibility (around 3–5 months of age). The
abundance of B cells observed in aged mice, most likely,
supports Th1 dominance, and thus facilitates the develop-
ment of PGIA.
Conclusion
Taken together as a whole, our data revealed that with age,
(i) the PG-immunization-induced T cell response
decreased, (ii) and although the amounts of cytokines
declined, Th1/Th2 cytokine balance was skewed toward
Th1 direction, and (iii) the (auto)antibody production
increased. Furthermore, in old mice, (iv) the T/B cell ratio
decreased, (v) but there was a clear shift towards memory
T cells, (vi) associated with a significant loss of
CD28+CD4+ cells. Other potentially important compo-
nents of immunosenescence in BALB/c mice included
(vii) disturbed Treg induction upon PG immunization,
(viii) several-fold increase of PG-activated T cells, and (ix)
altered myeloid/lymphoid-APC ratio at the site of antigen
injection (PLF).
In conclusion, immunosenescence is a physiological proc-
ess that can alter immunoregulatory functions in aging
individuals. We have identified some key aspects of the
aging immune system that could play a role in the age-
related autoimmune predisposition in BALB/c mice, thus
affect arthritis susceptibility and severity. Complex age-
related changes in T cell-APC interactions, and reduced
generation of Tregs may lead to impaired immune regula-
tion and development of autoimmune disease such as
PGIA, making this murine model even more relevant to
RA.
Methods
Antigens, animals, immunization, and sample collection
Human articular cartilage was collected from patients
who underwent knee joint replacement surgery. The col-
lection of cartilage from consenting patients was
approved by the Institutional Review Board of Rush Uni-
versity Medical Center (Chicago). Cartilage PG (aggrecan)
was extracted and depleted of glycosaminoglycan side
chains as described [25]. Mouse cartilage PG was prepared
by CsCl gradient centrifugation as described [23,43].
All animal procedures were conducted under a protocol
approved by the Institutional Animal Care and Use Com-
mittee of Rush University Medical Center. BALB/c mice
from Charles River Laboratories (Kingston Colony) were
bred in-house under specific pathogen-free conditions.
Siblings of 1 to 11 months of age were immunized intra-
peritoneally (i.p.) with an emulsion of cartilage PG (100
μg protein) and 2 mg dimethyldioctadecyl-ammonium
bromide (DDA) adjuvant on days 0, 21 and 42 [25]. Five
animals from each age group were sacrificed prior to
immunization (naive, non-immunized mice), or 10–15
days after the first, second and third immunizations. The
remaining animals were sacrificed 87 days after the first
PG/DDA injection (Table 1). Heparinized blood samples,
cells of peritoneal lavage fluid (PLF) and spleen cells were
collected at the time of sacrifice.
Clinical assessment of arthritis
PG-immunized mice were examined 3 times a week for
clinical symptoms of arthritis after the second immuniza-
tion. The time of onset and incidence of arthritis were
recorded, and severity was scored based upon swelling
and redness of each paw ranging from 0 to 4, yielding a
maximum severity score of 16 per mouse [20,25,41].
Measurement of antigen-specific antibodies and T cell 
responses
Serum samples and spleen cells were collected from naive
(non-immunized), and all immunized mice 87 days after
the first PG injection. PG-specific antibodies were meas-
ured by enzyme-linked immunosorbent assay (ELISA) as
described [25,29]. Sera were diluted at the range of 1:100–
1:102,400, and PG-specific antibodies were detected with
peroxidase-conjugated rabbit anti-mouse IgG1 and
IgG2a, respectively (Zymed Laboratories, San Francisco,
California, USA).
Antigen-specific T cell responses were measured in quad-
ruplicate samples of spleen cells (3 × 105 cells/well) cul-Immunity & Ageing 2009, 6:8 http://www.immunityageing.com/content/6/1/8
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tured in the presence of 50 μg human PG protein/ml or,
in an additional experiment, 25 μg mouse PG protein/ml.
IL-2 was measured on day 2 in 100 μl supernatant of PG-
stimulated spleen cell cultures using a CTLL-2 bioassay
[44]. T cell proliferation was assessed using [3H]thymi-
dine incorporation into spleen cells on day 5 [29,45].
Spontaneous and antigen-specific production of IL-4, IL-
6, IL-17, TNFα, and IFNγ were measured in cell culture
supernatants (1.8 × 106 cells/well) on day 5 using capture
ELISA (BD Biosciences, San Jose, California, USA or R&D
Systems, Minneapolis, Minnesota, USA) and the results
were expressed as pg amounts of cytokine secreted by 1 ×
106 cells [45].
Chemicals and monoclonal antibodies (mAbs)
All chemicals, unless indicated otherwise, were purchased
from Sigma Chemical Co. (St. Louis, Missouri, USA) or
Fischer Scientific (Chicago, Illinois, USA). Mouse recom-
binant cytokines and ELISA kits were purchased from
R&D Systems or BD Biosciences. Phosphate buffered
saline (PBS) was used for washing and storing cells until
use. Cell surface labeling with mAbs was carried out in
flow buffer [PBS containing 0.1% NaN3, 0.1% bovine
serum albumin (BSA)]. FoxP3 labeling was performed in
permeabilization buffer (eBiosciences, San Diego, CA)
after fixation of cells in fixation/permeabilization buffer
(eBiosciences).
The following mAbs purchased from BD Biosciences were
used: PerCP-Cy5.5-conjugated rat anti-mouse CD4 (clone
RM4-5), PE-Cy7-conjugated rat anti-mouse B220 (clone
RA3-6B2), APC-conjugated rat anti-mouse CD25 (clone
PC61), APC-Cy7-conjugated Armenian hamster anti-
mouse CD3 (clone 145-2C11), FITC-conjugated rat anti-
mouse IgD (clone 11-26c.2a), PE-conjugated rat anti-
mouse CD43 (clone S7), PerCP-Cy5.5-conjugated rat
anti-mouse IgM (clone R6-60.2), PE-Cy7-conjugated rat
anti-mouse CD19 (clone 1D3), APC-conjugated rat anti-
mouse CD5 (clone 53-7.3), biotin-conjugated rat anti-
mouse CD23 (clone B3B4), Alexa Fluor 488-conjugated
rat anti-mouse CD44 (clone IM7), and PE-conjugated rat
anti-mouse CD62L (clone MEL-14). The PE-conjugated
rat anti-mouse FoxP3 (clone FJK-16s), APC-conjugated
hamster anti-mouse CD28 (clone 37.51), APC-conju-
gated rat anti-mouse F4/80 (clone BM8). PE-Cy7-conju-
gated Armenian hamster anti-mouse CD11c (clone
N418) was purchased from eBiosciences.
Flow cytometry
We used a multicolor labeling technique for the simulta-
neous detection of cell surface and intracellular molecules
on PLF, spleen, and peripheral blood leukocytes. Briefly,
1 × 106 cells were seeded in 96-well U-bottom assay plates
(BD Falcon), Fc receptors blocked at 4°C in the dark for
15 min, and then incubated with mAb cocktails in 100 μl
flow cytometry staining buffer at 4°C in the dark for 30
min. Cells were washed twice, and finally resuspended in
200  μl of 0.1% buffered formaldehyde. If biotinylated
mAbs were used, after washing, fluorochrome-labeled
streptavidin was added to the samples and incubated at
4°C in the dark for another 30 min. FoxP3 was stained
after fixation and permeabilization of cells. Isotype-
matched control Abs for each specific mAb was used for
background staining in each experiment.
Samples were measured and analyzed in a FACS Canto II
flow cytometer (Becton Dickinson, San Jose, CA) using a
high-throughput-microplate module platform and DIVA
software. Initial gating was performed on lymphoid cells
based on forward/side scattering (FSC/SSC) properties.
Cell surface marker-defined populations were as follows:
CD3+: total T cells; CD3+ CD4+: CD4+ T cells; CD3+
CD8+: CD8+ T cells; CD4+ CD25+ FoxP3+: Tregs; B220+:
total B cells; IgDlow IgMhigh CD19+ CD23- CD5+/-: B1 cells
(B1a/b); IgDhigh IgMlow CD19+ CD23-: B2 cells [46]; F4/
80+: macrophages; and CD11c+: dendritic cells. We col-
lected data of 10,000 cells from the lymphoid gate in each
sample, unless otherwise stated. We used fluorescent his-
togram-, dot- and contour plots both for comparing mean
fluorescence intensities of different samples and calculat-
ing the ratio of positively stained cells.
Statistical analysis
Descriptive statistics were used to determine group means
and standard error of the mean (mean ± SEM). The differ-
ences between multiple groups were tested for statistical
significance using ANOVA. Two-tailed Pearson-correla-
tion analysis was used to find correlations between data
sets. A p < 0.05 value was considered to be statistically sig-
nificant.
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